RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: Aptamer 9.3t
Target: Coagulation Factor IXa (FIXa)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'-AUGGGGACUAUACCGCGUAAUGCUGCCUCCCCAU-3'
Sequence length: 34
GC content: 0.5588235294117647
Affinity: Kd: 0.58 ± 0.1 nM
Pool type: 5′-GGGAGAGAGGAAGAGGGAUGGG-N40-CAUAACCCAGAGGUCGAU-3′
Pool random region: 40
Binding buffer/conditions: 20 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM CaCl2, and 0.01% BSA
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Truncation of 9.3
Application as quoted in the referenced paper: Therapeutic: " Here we show that protein-binding oligonucleotides (aptamers) against coagulation factor IXa are potent anticoagulants. We also show that oligonucleotides complementary to these aptamers can act as antidotes capable of efficiently reversing the activity of these new anticoagulants in plasma from healthy volunteers and from patients who cannot tolerate heparin5. This generalizable strategy for rationally designing a drug–antidote pair thus opens up the way for developing safer regulatable therapeutics."
Additional information: Starting library contained 2'-fluoropyrimidines (2′F cytidine triphosphate and uridine triphosphate)
Reference (2002,Nature): Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., & Sullenger, B. A. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 419(6902), 90–94. https://doi.org/10.1038/nature00963
Aptamer: D-R16c
Target: D-arginine
Type of nucleic acid: ssRNA
Sequence: 5'CGGAUGGAAGGCGUGGUUAGAAUCCAAUAGCCCAUCCG3'
Sequence length: 38
GC content: 0.5526315789473685
Affinity: Kd: 135 ± 25 µM
Pool type: Not reported. The paper stated in vitro T7-transcription of a DNA template containing 50 randomized nucleotides flanked by two fixed 20-mer sequences
Pool random region: 50
Binding buffer/conditions: 320 mM NaCl, 50 mM Tris-HCI,  pH 7.5, and 5 mM MgCI, 
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Truncation: A short 38-mer aptamer containing the two sequences was chemi_x0002_cally synthesized based upon the secondary structure model. This truncated version of the aptamer, termed D-Rl6c, contains the structural clements necessary for specific binding to arginine 
Application as quoted in the referenced paper: Diagnostics: " Here we describe the mirror-design of a stable 38-mer L-oligori_x0002_bonucleotide ligand that binds to L-arginine. This L-RNA ligand was also able to bind to a short peptide containing the basic region of the human immunodeficiency virus type-1 Tat-protein. The L-RNA ligand displayed the expected stability in human serum. These findings may contribute to the identification of novel diagnostics and pharmaceuticals"
Additional information: An RNA library with 10" variants was generated by in vitro T7-transcription of a DNA template containing 50 randomized nucleotides flanked by two fixed 20-mer sequences for PCR amplification. The transcribed RNAs were selected on a o-arginine affinity column.
Reference (1996,Nat Biotechnol): Nolte, A., Klussmann, S., Bald, R., Erdmann, V. A., & Fürste, J. P. (1996). Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nature biotechnology, 14(9), 1116–1119. https://doi.org/10.1038/nbt0996-1116
Aptamer: L-R16c
Target: L-arginine
Type of nucleic acid: ssRNA
Sequence: 5'CGGAUGGAAGGCGUGGUUAGAAUCCAAUAGCCCAUCCG3'
Sequence length: 38
GC content: 0.5526315789473685
Affinity: Kd:  129 ± 18 µM
Pool type: Not reported. The paper stated in vitro T7-transcription of a DNA template containing 50 randomized nucleotides flanked by two fixed 20-mer sequences
Pool random region: 50
Binding buffer/conditions: 320 mM NaCl, 50 mM Tris-HCI,  pH 7.5, and 5 mM MgCI, 
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Truncation: A short 38-mer aptamer containing the two sequences was chemi_x0002_cally synthesized based upon the secondary structure model. This truncated version of the aptamer, termed D-Rl6c, contains the structural clements necessary for specific binding to arginine 
Application as quoted in the referenced paper: Diagnostics: " Here we describe the mirror-design of a stable 38-mer L-oligori_x0002_bonucleotide ligand that binds to L-arginine. This L-RNA ligand was also able to bind to a short peptide containing the basic region of the human immunodeficiency virus type-1 Tat-protein. The L-RNA ligand displayed the expected stability in human serum. These findings may contribute to the identification of novel diagnostics and pharmaceuticals"
Additional information: An RNA library with 10" variants was generated by in vitro T7-transcription of a DNA template containing 50 randomized nucleotides flanked by two fixed 20-mer sequences for PCR amplification. The transcribed RNAs were selected on a o-arginine affinity column.
Reference (1996,Nat Biotechnol): Nolte, A., Klussmann, S., Bald, R., Erdmann, V. A., & Fürste, J. P. (1996). Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nature biotechnology, 14(9), 1116–1119. https://doi.org/10.1038/nbt0996-1116
Aptamer: A10-3
Target: Prostate-Specific Membrane Antigen (PSMA) of prostate cancer cells
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGGC3'
Sequence length: 56
GC content: 0.5535714285714286
Affinity: ki: 20.5 nM
Pool type: 5′-GGGAGGACGAUGCGG-40N-CAGACGACUCGCCCGA-3'
Pool random region: 40
Binding buffer/conditions: HBSMCIT [HBSMC [HEPES buffered saline (pH 7.4), 1 mm MgCl2, and 1 mm CaCl2], 0.01% I-block (Tropix Inc., Bedford, MA), and 0.05% Tween 20]
Divalent salt: MgCl/CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: ptamer Truncations. Both aptamers were subjected to 3_x0004_-trun_x0002_cation in five-nucleotide increments to identify the minimal required binding elements. Truncation of xPSM-A9 past five nucleotides resulted in loss of PSMA inhibition, whereas xPSM-A10 could be  truncated by up to 15 nucleotides while retaining PSMA binding ability. This truncated aptamer, named xPSM-A10-3, is approximately Mr 18,500 and retains the ability to competitively inhibit xPSM NAALADase activity with a calculated Ki of 20.5 nM (Fig. 3C). Additional truncation of xPSM-A10-3 on the 5_x0004_-end resulted in loss of the ability to bind xPSM.
Application as quoted in the referenced paper: Therapeutic: " These are the first reported RNA aptamers selected to bind a tumor-associated membrane antigen and the first application of RNA aptamers to a prostate specific cell marker. These aptamers may be used clinically as NAALADase inhibitors or be modified to carry imaging agents and therapeutic agents directed to prostate cancer cells."
Additional information: pool modified with 2′F-CTP, 2′F-UTP, ATP, GTP. DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection..
Reference (2002,Cancer Res): Lupold, S. E., Hicke, B. J., Lin, Y., & Coffey, D. S. (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer research, 62(14), 4029–4033.
Aptamer: A10-3.2-Chimeras (Stem loop)
Target: Prostate-Specific Membrane Antigen (PSMA)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGCGGCUUUGCCAAGUGCUUGGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCUAAGCAUUGGCAAAGCCGCCCUU3'
Sequence length: 82
GC content: 0.573170731707317
Affinity: Kd: 2.9 nM
Pool type: 5′-TCGCGCGAGTCGTCTG-40N-CCGCATCGTCCTCCC-3′
Pool random region: 40
Binding buffer/conditions: Dulbecco's phosphate-buffered saline with MgCl2 and CaCl2 (Life Technologies, Inc.) and 0.05% bovine serum albumin
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 13 kDa
Post-SELEX modifications: Truncation: To facilitate chemical synthesis, we reduced the aptamer portion of the A10-Plk1chimera from 71 (corresponding to original A10 aptamer)26 to 39 nucleotides (nt) (A10-3.2 aptamer)).
Application as quoted in the referenced paper: Therapeutic: "We also truncated the aptamer portion of the chimeras to facilitate large-scale chemical synthesis. The optimized chimeras resulted in pronounced regression of PSMA-expressing tumors in athymic mice after systemic administration. Anti-tumor activity was further enhanced by appending a polyethylene glycol moiety, which increased the chimeras’ circulating half-life."
Additional information: pool modified with 2′F-CTP, 2′F-UTP, ATP, GTP. DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection..

Many of the information was extracted from parent paper which may include pool type and binding buffer (https://pubmed.ncbi.nlm.nih.gov/11590140/)

The Kd is Relative affinity of A10 PSMA aptamer and truncated A10 aptamers to cells expressing PSMA.
Reference (2009,Nat Biotechnol): Dassie, J. P., Liu, X. Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., 2nd, & Giangrande, P. H. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nature biotechnology, 27(9), 839–849. https://doi.org/10.1038/nbt.1560
Aptamer: sga16
Target: Human T-cell acute lymphoblastic leukemia CCRF-CEM cells (later identified to bind PTK-7)
Type of nucleic acid: ssDNA
Sequence: 5'ATACCAGCTTATTCAATTAGTCACACTTAGAGTTCTAGCTGCTGCGCCGCCGGGAAAATACTGTACGGATAGATAGTAAGTGCAATCT3'
Sequence length: 88
GC content: 0.4318181818181818
Affinity: Kd: 5.00 ± 0.52 nM
Pool type: 5'-ATACCAGCTTATTCAATT-52N-AGATAGTAAGTGCAATCT-3'
Pool random region: 52
Binding buffer/conditions: 4.5 g/liter glucose and 5 mM MgCl2 in Dulbecco's PBS with calcium chloride and magnesium chloride (Sigma) and adding yeast tRNA (0.1 mg/ml; Sigma) and BSA (1 mg/ml; Fisher)
Divalent salt: MgCl 
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Biosensor: "Using cell-based aptamer selection, we have developed a strategy to use the differences at the molecular level between any two types of cells for the identification of molecular signatures on the surface of targeted cells. A group of aptamers have been generated for the specific recognition of leukemia cells. The selected aptamers can bind to target cells with an equilibrium dissociation constant (Kd) in the nanomolar-to-picomolar range. The cell-based selection process is simple, fast, straightforward, and reproducible, and, most importantly, can be done without prior knowledge of target molecules. The selected aptamers can specifically recognize target leukemia cells mixed with normal human bone marrow aspirates and can also identify cancer cells closely related to the target cell line in real clinical specimens. The cell-based aptamer selection holds a great promise in developing specific molecular probes for cancer diagnosis and cancer biomarker discovery."
Additional information: The aptamer sequence was obtained from the 2007 paper, while the pool information and others such application obtained from 2006 paper (https://doi.org/10.1073/pnas.0602615103)
Reference (2007,Chembiochem): Shangguan, D., Tang, Z., Mallikaratchy, P., Xiao, Z., & Tan, W. (2007). Optimization and modifications of aptamers selected from live cancer cell lines. Chembiochem : a European journal of chemical biology, 8(6), 603–606. https://doi.org/10.1002/cbic.200600532
Aptamer: A10-3.2
Target: Prostate-Specific Membrane Antigen (PSMA)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCU3'
Sequence length: 39
GC content: 0.5641025641025641
Affinity: Kd: 2.9 nM
Pool type: 5′-TCGCGCGAGTCGTCTG-40N-CCGCATCGTCCTCCC-3′
Pool random region: 40
Binding buffer/conditions: Dulbecco's phosphate-buffered saline with MgCl2 and CaCl2 (Life Technologies, Inc.) and 0.05% bovine serum albumin
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 13 kDa
Post-SELEX modifications: Truncation: To facilitate chemical synthesis, we reduced the aptamer portion of the A10-Plk1chimera from 71 (corresponding to original A10 aptamer)26 to 39 nucleotides (nt) (A10-3.2 aptamer)).
Application as quoted in the referenced paper: Therapeutic: "We also truncated the aptamer portion of the chimeras to facilitate large-scale chemical synthesis. The optimized chimeras resulted in pronounced regression of PSMA-expressing tumors in athymic mice after systemic administration. Anti-tumor activity was further enhanced by appending a polyethylene glycol moiety, which increased the chimeras’ circulating half-life."
Additional information: pool modified with 2′F-CTP, 2′F-UTP, ATP, GTP. DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection..

Many of the information was extracted from parent paper which may include pool type and binding buffer (https://pubmed.ncbi.nlm.nih.gov/11590140/)

The Kd is Relative affinity of A10 PSMA aptamer and truncated A10 aptamers to cells expressing PSMA.
Reference (2009,Nat Biotechnol): Dassie, J. P., Liu, X. Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., 2nd, & Giangrande, P. H. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nature biotechnology, 27(9), 839–849. https://doi.org/10.1038/nbt.1560
Aptamer: C2.min
Target: Human transferrin receptor (hTfR), CD71 (TfR)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGGGAUCAAUCCAAGGGACCCGGAAACGCUCCCUUACACCCC3'
Sequence length: 42
GC content: 0.711
Affinity: Kd:102 nM
Pool type: 5′-GGGAGGTGAATGGTTCTACGAT-N50-TTACATGCGAGATGACCACGTAATTGAATTAAATGCCCGCCATGACCAG-3′
Pool random region: 50
Binding buffer/conditions: HBSS (Hank's Buffered Saline Solution; Invitrogen)
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Truncation: "More importantly, our analysis allowed us to identify a minimal aptamer comprised of 42 nucleotides, c2.min, in which we shortened the terminal stem formed between the 3′ and 5′ ends and replaced the terminal loop with a stable GNRA tetraloop"
Application as quoted in the referenced paper: Drug Delivery: "Selected aptamers were specific for the human receptor, rapidly endocytosed by cells and shared a common core structure. A minimized variant was found to compete with the natural ligand, transferrin, for receptor binding and cell uptake, but performed ~twofold better than it in competition experiments. Using this molecule, we generated aptamer-targeted siRNA-laden liposomes. Aptamer targeting enhanced both uptake and target gene knockdown in cells grown in culture when compared to nonmodified or nontargeted liposomes. The aptamer should prove useful as a surrogate for transferrin in many applications including cell imaging and targeted drug delivery."
Additional information: "The 2′F modification can be readily incorporated during transcription by substituting 2′F CTP and 2′F UTP instead of the natural CTP and UTP and using the mutant T7 RNA polymerase protein Y639F"
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection..
"additional 3′ constant region used for hybridization of a fluorescent probe for flow cytometry"
Reference (2012,Mol Ther Nucleic Acids
): Wilner, S. E., Wengerter, B., Maier, K., de Lourdes Borba Magalhães, M., Del Amo, D. S., Pai, S., Opazo, F., Rizzoli, S. O., Yan, A., & Levy, M. (2012). An RNA alternative to human transferrin: a new tool for targeting human cells. Molecular therapy. Nucleic acids, 1(5), e21. https://doi.org/10.1038/mtna.2012.14
Aptamer: Waz
Target: Human transferrin receptor (hTfR)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGUUCUACGAUAAACGGUUAAUGAUCAGCUUAUGGCUGGCAGUUCCC3'
Sequence length: 48
GC content: 0.4791666666666667
Affinity: Kd: 390 ± 40
Pool type: 5′GGGAGGTGAATGGTTCTACGAT-N50-TTACATGCGAGATGACCACGTAATTGAATTAAATGCCCGCCATGACCAG-3′
Pool random region: 50
Binding buffer/conditions: Not Reported 
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Truncation: "We minimized the lead sequence from Family 1 (clone 10–36) through an iterative process of truncation and testing based on the mFold-predicted secondary structure"
Application as quoted in the referenced paper: Drug Delivery: "Waz's ability to bind and be internalized by hTfR-positive cells independent of Tf binding makes it an attractive candidate for a variety of other applications ranging from targeted drug delivery, to the development of diagnostics and imaging agents, or as a means to enhance the delivery of macromolecules across the blood–brain barrier."
Additional information: The resultant minimized aptamer, Waz, binds the apical domain of the receptor and inhibits infection of human cells by recombinant NWM in culture (EC50 ≃400 nmol/l). Aptamer multimerization further enhanced inhibition >10-fold (EC50 ≃30 nmol/l).
"The 2′F modification can be readily incorporated during transcription by substituting 2′F CTP and 2′F UTP instead of the natural CTP and UTP and using the mutant T7 RNA polymerase protein Y639F"
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection..
"additional 3′ constant region used for hybridization of a fluorescent probe for flow cytometry"
Reference (2016,Mol Ther Nucleic Acids
): Maier, K. E., Jangra, R. K., Shieh, K. R., Cureton, D. K., Xiao, H., Snapp, E. L., Whelan, S. P., Chandran, K., & Levy, M. (2016). A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry. Molecular therapy. Nucleic acids, 5, e321. https://doi.org/10.1038/mtna.2016.32
Aptamer: CL4
Target: Epidermal growth factor receptor (EGFR)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GCCUUAGUAACGUGCUUUGAUGUCGAUUCGACAGGAGGC3'
Sequence length: 39
GC content: 0.5128205128205128
Affinity: Kd: 38 nM
Pool type: Not Reported 
Pool random region: 45
Binding buffer/conditions: Not Reported 
Buffer type: Not Reported
Molecular weight of target: 175 KDa
Post-SELEX modifications: Truncation: " Based on the predicted secondary structure of the 92mer original molecule, we designed a shorter aptamer of 39mer (herein indicated as CL4) containing the functional site of CL4 FL (Fig. 1A) that preserves high binding affinity to A549 cells with a Kd of 38 nM and discriminates them from H460 cells"
Application as quoted in the referenced paper: Inhibition: " Interestingly, combined treatment with cetuximab and the aptamer shows clear synergy in inducing apoptosis in vitro and in vivo. In conclusion, we demonstrate that this neutralizing RNA-aptamer is a promising bio-molecule that can be developed as a more effective alternative to the repertoire of already existing EGFR-inhibitors."
Additional information: A library of 2′F-Py RNAs containing a central stretch of 45 random nucleotides was subjected to a differential SELEX protocol against NSCLC. At each round, the positive selection step on A549 cells was preceded by one or two counterselection steps against H460 cells and the SELEX cycle was performed
Reference (2011,PLoS One
): Esposito, C. L., Passaro, D., Longobardo, I., Condorelli, G., Marotta, P., Affuso, A., de Franciscis, V., & Cerchia, L. (2011). A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PloS one, 6(9), e24071. https://doi.org/10.1371/journal.pone.0024071
Aptamer: EpDT3
Target: Epithelial cell adhesion molecule (EpCAM), also known as CD326 or ESA
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5′GCGACUGGUUACCCGGUCG3'
Sequence length: 19
GC content: 0.6842105263157895
Affinity: Kd~ 12 ± 6.5
Pool type: Not Reported 
Pool random region: 40
Binding buffer/conditions: DPBS containing 5mM MgCl2, 0.1mg/mL tRNA, and 0.1mg/mL salmon sperm DNA
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
Molecular weight of target: 30–40 kDa
Post-SELEX modifications: Truncation: " Thus, we carried out serial truncation of the original EpCAM aptamer Clone D, based on the assumption that the end loop on the left of the 2-D structure of Clone D (Fig. 2A) was responsible for the binding of the aptamer to EpCAM. Two rounds of truncation shortened Clone D first to 43 nt, then further down to 19 nt (Fig. 2B,C). The K’d for the shortest 3′-FITC-labeled EpCAM aptamer, EpDT3 (5′-GCGACUGGUUACCCGGUCG-3′), was 12 ± 6.5 nM, when analyzed using Kato III cells (Fig. 2D–F)."
Application as quoted in the referenced paper: Therapeutic: "Importantly, this EpCAM RNA aptamer is efficiently internalized after binding to cell surface EpCAM. To our knowledge, this is the first RNA aptamer against a cancer stem cell surface marker being developed. Such cancer stem cell aptamers will greatly facilitate the development of novel targeted nanomedicine and molecular imaging agents for cancer theranostics." & "Given the varying success of current anti-EpCAM antibody therapy, we sought to develop a nuclease-resistant aptamer targeting the cancer stem cell marker that could have diagnostic and therapeutic potential. Herein, we describe the selection and characterisation of an RNA aptamer against EpCAM."
Additional information: A random RNA library of approximately 1 × 1014 species containing 2′-fluoro-modified ribose on all pyrimidines was used to incubate with immobilized recombinant EpCAM.
Reference (2011,Cancer Sci): Shigdar, S., Lin, J., Yu, Y., Pastuovic, M., Wei, M., & Duan, W. (2011). RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer science, 102(5), 991–998. https://doi.org/10.1111/j.1349-7006.2011.01897.x
Aptamer: SE15-8mini
Target: Epithelial cell adhesion molecule (EpCAM) 
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5′AGCCGCGAGGGGAGGGAUAGGGUAGGGCGCGGCU3′
Sequence length: 34
GC content: 0.7352941176470589
Affinity: Kd: 3.49 ± 1.3
Pool type: 5'-CGGAATTCGTAATACGACTCACTATAGGGACGCGTGGTACC-N50-AAGCTTCCGCGGGGATCCAA3'
Pool random region: 50
Binding buffer/conditions: 20 mM HEPES (pH 7.0), 150 mM NaCl, 1 mM MgCl2, 2 mM dithiothreitol, and 40 U RNase inhibitor
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7
Molecular weight of target: Not reported
Post-SELEX modifications: Truncation: "SE15-8 truncated mini RNA aptamer (Mini)."
Application as quoted in the referenced paper: Therapeutic: "In the present study, we isolated the RNA aptamer for ErbB2 and showed it to have high affinity to extracellular domain of ErbB2 protein. We also generated a minimized version of RNA aptamer (mini-aptamer), which demonstrated high specificity to ErbB2-positive, but not EGFR-positive, cancer cell lines. The selected RNA aptamer is a potentially useful cancer imaging agent by targeting ErbB2-overexpressing malignant cells."
Additional information: The 2′-fluorine-modified RNA (2′ FY-RNA) library consisted of T7 in vitro transcription with the random DNA libraries (1.0 × 1014 molecules) and modified NTPs (Epicentre, Madison, WI)
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection..

Reference (2011,Nucleic Acid Ther): Kim, M. Y., & Jeong, S. (2011). In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic acid therapeutics, 21(3), 173–178. https://doi.org/10.1089/nat.2011.0283